CERo Therapeutics Holdings, Inc.
CERO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,163 | $1,117 | $0 | $0 |
| Gross Profit | -$1,163 | -$1,117 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,316 | $0 | $9,846 | $9,137 |
| G&A Expenses | $8,985 | $3 | $2,126 | $2,479 |
| SG&A Expenses | $8,985 | $2,893 | $2,841 | $2,479 |
| Sales & Mktg Exp. | $0 | $2,890 | $716 | $0 |
| Other Operating Expenses | $0 | $40 | -$9,782 | -$11,185 |
| Operating Expenses | $15,301 | $2,933 | $2,905 | $431 |
| Operating Income | -$15,301 | -$2,933 | -$2,905 | -$332 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7,569 | $492 | $2,837 | -$0 |
| Pre-Tax Income | -$7,732 | -$2,441 | -$69 | -$332 |
| Tax Expense | $0 | $95 | $599 | -$17 |
| Net Income | -$7,732 | -$3 | -$668 | -$316 |
| % Margin | – | – | – | – |
| EPS | -6.87 | -2,497.2 | -19.73 | -2.75 |
| % Growth | 99.7% | -12,556.9% | -617.5% | – |
| EPS Diluted | -6.87 | -2,497.2 | -19.73 | -2.75 |
| Weighted Avg Shares Out | 121 | 7 | 7 | 7 |
| Weighted Avg Shares Out Dil | 121 | 7 | 7 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27 | $138 | $2,837 | $987 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,163 | $3 | $2,905 | $735 |
| EBITDA | -$6,569 | -$2,438 | -$69 | $403 |
| % Margin | – | – | – | – |